| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.0021 | 0.9 |